US 12,378,317 B2
PD-L 1-binding polypeptide and use thereof
Tao Xu, Suzhou (CN); Yan Sun, Suzhou (CN); Hao Qi, Suzhou (CN); Haijing Du, Suzhou (CN); Tingting Hu, Suzhou (CN); Yanling Yang, Suzhou (CN); Fangfang Li, Suzhou (CN); Qi Zhao, Suzhou (CN); and Songbing Qin, Suzhou (CN)
Assigned to Suzhou Smartnuclide Biopharmaceutical Co., Ltd., Jiangsu (CN)
Filed by Suzhou Smartnuclide Biopharmaceutical Co., Ltd., Suzhou (CN)
Filed on Dec. 29, 2020, as Appl. No. 17/137,188.
Application 17/137,188 is a continuation of application No. PCT/CN2019/093225, filed on Jun. 27, 2019.
Claims priority of application No. 201810696663.X (CN), filed on Jun. 29, 2018.
Prior Publication US 2021/0253709 A1, Aug. 19, 2021
Int. Cl. C07K 16/28 (2006.01); A61K 51/10 (2006.01); G01N 33/574 (2006.01)
CPC C07K 16/2827 (2013.01) [A61K 51/1027 (2013.01); A61K 51/1045 (2013.01); G01N 33/57492 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2317/92 (2013.01)] 14 Claims
OG exemplary drawing
 
1. A programmed death ligand 1 (PD-L1) binding polypeptide
which is capable of specifically binding to PD-L1 and comprises at least one immunoglobulin single variable domain, wherein the at least one immunoglobulin single variable domain comprises:
CDR1, which comprises the amino acid sequence set forth in SEQ ID NO: 5,
CDR2, which comprises the amino acid sequence set forth in SEQ ID NO: 6 or the amino acid sequence set forth in SEQ ID NO: 13, and
CDR3, which comprises the amino acid sequence set forth in SEQ ID NO: 7.